A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer

被引:3
|
作者
Kato, Takuma [1 ,2 ]
Tohi, Yoichiro [1 ]
Honda, Tomoko [1 ]
Matsuda, Iori [1 ]
Osaki, Yu [1 ]
Naito, Hirohito [1 ]
Matsuoka, Yuki [1 ]
Okazoe, Homare [1 ]
Taoka, Rikiya [1 ]
Tsunemori, Hiroyuki [1 ]
Ueda, Nobufumi [1 ]
Sugimoto, Mikio [1 ]
机构
[1] Kagawa Univ, Fac Med, Dept Urol, Kita, Kagawa, Japan
[2] Kagawa Univ, Fac Med, Dept Urol, 1750-1,Ikenobe, Kita, Kagawa 7610793, Japan
关键词
active surveillance; Gleason score; prostate cancer; survey; urologic oncology; TERM OUTCOMES; GRADE; MEN;
D O I
10.1111/iju.15102
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To conduct a national questionnaire survey of Japanese urologists on active surveillance (AS) for low- and intermediate-risk prostate cancer (PCa). Methods: A questionnaire was sent to 922 Japanese Urological Association Teaching Base Hospitals. The items included were years of experience as a urologist, sex, workplace, treatment equipment owned, specialty area of daily practice, specialty area of urological cancer, and six hypothetical cases of AS. The cases were categorized by the following Gleason scores: 3 + 3 low risk of PCa, 3 + 4 intermediate risk, and 4 + 3 intermediate risk, with or without comorbidities for each case. Comorbidities were defined as cardiovascular diseases or illnesses warranting anticoagulant therapy. Results: Altogether, 1962 questionnaires were analyzed. Responses were almost equally distributed among all age groups. Workplaces included general hospitals (49.4%), university hospitals (40.3%), and cancer centers (4.2%). Percentages of proposed AS for low risk/no comorbidity, low risk/with comorbidity, intermediate-risk 3 + 4/no comorbidity, intermediate risk 3 + 4/with comorbidity, intermediate risk 4 + 3/no comorbidity, and intermediate risk 4 + 3/with comorbidity were 90.5%, 90%, 39.5%, 48.7%, 15%, and 22%, respectively. Analysis of the correspondents' backgrounds showed that the more the urologists' years of experience, the less they were to advise AS of low-risk patients. In the presence of comorbidities, urologists across all age groups tended to propose AS, even in the same Gleason grade group. Cancer center urologists recommended AS more often than their counterparts at general and university hospitals. Conclusions: Approximately 40% of urologists proposed AS for intermediate-risk cases, confirming that AS for intermediate-risk patients is being considered in Japan.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [1] Editorial Comment to "A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer"
    Matsumoto, Ryuji
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 297 - 297
  • [2] Editorial Comment on a national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer
    Kishida, Takeshi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (03) : 298 - 298
  • [3] Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists
    Kim, Simon P.
    Shah, Nilay D.
    Meropol, Neal J.
    Tilburt, Jon C.
    Nguyen, Paul L.
    Yu, James B.
    Abouassaly, Robert
    Kim, Albert
    Gross, Cary P.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (02): : 189 - 195
  • [4] Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
    Courtney, P. Travis
    Deka, Rishi
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Salans, Mia A.
    Nelson, Tyler J.
    Kumar, Abhishek
    Luterstein, Elaine
    Yip, Anthony T.
    Nalawade, Vinit
    Parsons, J. Kellogg
    Kader, A. Karim
    Stewart, Tyler F.
    Rose, Brent S.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 151 - +
  • [5] Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance
    Zambrano, Ibardo A.
    Hwang, Soohyun
    Basak, Ram
    Spratte, Brooke Namboodri
    Filson, Christopher P.
    Jacobs, Bruce L.
    Tan, Hung-Jui
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (09) : 388.e1 - 388.e8
  • [6] Active surveillance in intermediate-risk prostate cancer
    Klotz, Laurence
    [J]. BJU INTERNATIONAL, 2020, 125 (03) : 346 - 354
  • [7] Active surveillance for intermediate-risk prostate cancer
    M A Dall'Era
    L Klotz
    [J]. Prostate Cancer and Prostatic Diseases, 2017, 20 : 1 - 6
  • [8] Active surveillance for intermediate-risk prostate cancer
    Dall'Era, M. A.
    Klotz, L.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (01) : 1 - 6
  • [9] Active surveillance for intermediate-risk prostate cancer
    Nayan, Madhur
    Carvalho, Filipe L. F.
    Feldman, Adam S.
    [J]. WORLD JOURNAL OF UROLOGY, 2022, 40 (01) : 79 - 86
  • [10] Active surveillance for intermediate-risk prostate cancer
    Madhur Nayan
    Filipe L. F. Carvalho
    Adam S. Feldman
    [J]. World Journal of Urology, 2022, 40 : 79 - 86